Publications by authors named "Saad Mazhar"
Article Synopsis
- Non-alcoholic steatohepatitis (NASH) is a serious illness with limited treatment options, and the FDA has recently approved resmetirom, a drug targeting the thyroid hormone receptor, for its treatment.
- In a review of four randomized controlled trials, resmetirom notably improved MRI-proton density fat fraction, reduced liver fat by 30%, and resolved NASH without fibrosis, although effects on certain liver enzymes were mixed.
- Resmetirom was linked to significant drops in various lipid levels (like triglycerides and LDL), but it also increased the likelihood of side effects such as diarrhea and nausea in patients.
Article Synopsis
- Hospitalized COVID-19 patients face a high risk of thromboembolism and death, creating a need to compare the safety and effectiveness of factor Xa inhibitors versus enoxaparin for prevention.
- A systematic review of studies revealed 4048 patients, showing that factor Xa inhibitors reduced thromboembolism incidence compared to enoxaparin, but results varied significantly by study type.
- The analysis concluded that while factor Xa inhibitors appear more effective in preventing thromboembolism later than during acute illness, there was no significant difference in bleeding or overall mortality rates between the two medications.
Background: The optimal treatment regimen for patients with Hughes syndrome remains unclear. Therefore, the authors sought to compare the outcomes of warfarin vs. factor Xa inhibitors in patients with Hughes syndrome.
View Article and Find Full Text PDFBackground: Cerebral venous thromboembolism (CVT) poses a significant risk of venous infarction and haemorrhage, which can lead to neurological deficits and, in severe cases, even death. The optimal treatment regimen for patients with CVT remains unclear.
Methods: MEDLINE, Embase, Google Scholar, Web of Science (WoS), and Cochrane Central databases were searched for randomized controlled trials (RCTs) and observational studies assessing the efficacy and safety of rivaroxaban in patients with CVT.
Background: Patients with non-valvular atrial fibrillation with diabetes face increased stroke and cardiovascular risks. This study compares factor Xa inhibitors and warfarin using data from randomized controlled trials (RCTs).
Methods: MEDLINE, Embase, and Cochrane CENTRAL databases were searched for RCTs comparing the risk of efficacy and safety of any factor Xa inhibitors with dose-adjusted warfarin by diabetes status.
Cystic echinococcosis (CE), or hydatid disease, is a parasitic infection caused by endemic to areas with considerable pastoral farming and animal husbandry. Typical presentations include hydatid cyst formation in the liver, lungs, brain, kidneys, or bones. An isolated splenic hydatid cyst is an extremely rare occurrence, accounting for only 0.
View Article and Find Full Text PDF